HOME    
   ABOUT SRCLD    
     :: History    
     :: Committees    
     :: Contact Us    
   CALL FOR PAPERS    
     :: Guidelines    
     :: Online Submission    
     :: Poster Preparation    
   REGISTRATION    
     :: Guidelines    
     :: Online Registration    
   PROGRAM    
     :: Schedule    
     :: Tutorial    
     :: Oral Presentations    
     :: Invited Speakers    
     :: Poster Presentations    
   MY AGENDA    
     :: Instructions    
     :: My Agenda    
   ACCOMMODATIONS    
     :: General Information    
     :: Lodging    
     :: Directions/Parking    
     :: Convention Center    
   TRAVEL AWARDS    
     :: General Information    
     :: Online Application    
   PUBLISHERS    
     :: Become An Exhibitor    
     :: Recent Publications    
   SEARCH    
     :: Past SRCLDs    
     :: Search    
 SRCLD Presentation Details 

  Title  
       
    Rethinking Clinical Trials in Neurodevelopmental Disabilities: Contributions from Language Assessment and Intervention  
Author(s)
Leonard Abbeduto - UC Davis MIND Institute

SRCLD Info
SRCLD Year: 2020
Presentation Type: Invited Speaker
Presentation Time: Sat, May 30, 2020 at 10:30 AM
Abstract
In the past decade, dozens of medications targeting core and comorbid symptoms of fragile X syndrome, Down syndrome, autism spectrum disorder, and other neurodevelopmental disabilities have been developed and tested. Despite promising findings in preclinical studies involving a number of species, these medications have largely failed to show benefit in human studies. A number of reasons have been proposed for these “failures of translation.” In our research, we have focused on addressing two points of failure: (1) the use of psychometrically inadequate and poorly motivated outcome measures and (2) reliance on a clinical trials paradigm that is poorly suited to detecting changes in learning and behavior in individuals with neurodevelopmental disabilities. We have proposed that it would be useful to target language as an outcome measure in treatment studies because changes in language would be functional and meaningful for the individual. We have also proposed that medications are more likely to lead to detectable change, especially in short-term studies, if paired with behavioral or educational therapies that optimize the learning environment. In this presentation, I will present findings from two lines of research, one focused on evaluating the psychometric properties of outcome measures derived from expressive language sampling and the other focused on the development of telehealth-delivered, parent-implemented language interventions that can be useful complements to medication. The data to be presented are derived from studies of fragile X syndrome, Down syndrome, and autism spectrum disorder. This research has been supported by the National Institutes of Health through grants R01HD074346, R01HD024356, U54HD079125, and U01NS096767, with additional funding provided by the Simons Foundation and the National Fragile X Foundation.
Author Biosketch(es)

 

Supported in part by: NIDCD and NICHD, NIH, R13 DC001677, Susan Ellis Weismer, Principal Investigator
University of Wisconsin-Madison - Department of Communication Sciences and Disorders